Medytox Achieves KRW 68.7 Billion in Q2 Sales with Rapid Market Entry of New Drug 'Newviju', Up 11.4% Year-on-Year

Operating and Net Profits Decline
Due to Costs Associated with Business Expansion

Medytox saw an increase in second-quarter revenue, driven by the rapid market entry of its fat reduction injectable 'Newviju' and the growth of its toxin and filler businesses both domestically and internationally. However, operating profit and net profit declined due to rising costs associated with business expansion.

On August 10, Medytox announced in its earnings report that consolidated sales for the second quarter reached 68.7 billion won, up 11.4% year-on-year. During the same period, operating profit dropped by 24.6% to 4.8 billion won, while net profit fell by 61.7% to 3.1 billion won.

Sales of botulinum toxin products continued both in Korea and abroad, and international filler business also expanded sales, particularly in major countries, contributing to revenue growth. Despite intensified competition in the domestic toxin market, the company explained that overall growth was maintained through its product lineup centered around 'Coretox.'

Medytox added that 'Newviju,' the 40th locally developed pharmaceutical product for fat reduction in Korea, has quickly established itself in the market since launch and is emerging as a new growth engine. In contrast, revenue from the domestic filler market saw a slight year-on-year decline, affected by intensified competition and changes in the market environment. The company further explained that beauty and healthcare businesses, such as the derma-cosmetic 'Neuraderm' and the fat reduction probiotic 'Lactiplan,' along with portfolio expansion in aesthetics, had only a limited impact on overall business growth.

For the second half of the year, Medytox plans to strengthen its business competitiveness by expanding the market for 'Newviju,' reinforcing academic programs for healthcare professionals, and pursuing further promotion in global markets.

A Medytox official stated, "Our core products both at home and abroad are maintaining steady growth, and in Korea, 'Newviju' is establishing its presence in the market more rapidly than expected." He added, "We will nurture 'Newviju' as a new growth pillar and continue to enhance the global competitiveness of our toxin and filler businesses to sustain our growth trajectory."

This content was produced with the assistance of AI translation services.